In 71.4% of cases, preceding trauma to the skin was reported. Outcomes included the misdiagnosis rate, treatment, and maternal and fetal complications. TAKEAWAY: ...

Pyoderma Gangrenosum: Pain Identified as Reliable Patient-Reported Outcome Doug Brunk September 21, 2023 0 ...

In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology ...

SPOKANE, Wash. – Ryan Becker, a Spokane resident, is battling an extremely rare skin condition known as pyoderma gangrenosum. After visits to the Mayo Clinic and Johns Hopkins, Becker has been ...

Phase 3 pyoderma gangrenosum trial was halted after analysis of 30 patients showed no efficacy signal. InflaRx to prioritize INF904 with key data expected in chronic spontaneous urticaria and ...

The independent data monitoring committee assessing a phase 3 trial of vilobelimab in pyoderma gangrenosum (PG) has urged InflaRx to stop the study early for futility.

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. PG is a rare and debilitating autoimmune skin ...